Course: Risks of SARS-CoV-2 Breakthrough Infection and Hospitalization in Fully Vaccinated Patients With Multiple Myeloma
CME Credits: 1.00
Released: 2021-11-23
Data from early in the COVID-19 pandemic when vaccines were not available showed that patients with multiple myeloma (MM) were at increased risk for COVID-19 infection and severe outcomes., Recent studies showed a low rate of seroconversion after messenger RNA (mRNA) anti-SARS-CoV-2 vaccination in patients with MM and other hematological malignant neoplasms., However, the risk and outcomes of SARS-CoV-2 breakthrough infection in vaccinated patients with MM remains unknown.
Educational Objective
To identify the key insights or developments described in this article
View Full Course